keyword
MENU ▼
Read by QxMD icon Read
search

Hypoactive sexual desire disorder

keyword
https://www.readbyqxmd.com/read/29310164/re-men-s-sexual-response-to-female-partner-s-intranasal-oxytocin-administration-for-hypoactive-sexual-desire-disorder-an-open-prospective-cohort-study
#1
https://www.readbyqxmd.com/read/29289374/safety-of-flibanserin-in-women-treated-with-antidepressants-a-randomized-placebo-controlled-study
#2
Anita H Clayton, Harry A Croft, James Yuan, Louise Brown, Robert Kissling
BACKGROUND: Depression is often associated with sexual dysfunction, and pharmacologic treatment for hypoactive sexual desire disorder can be considered in women receiving treatment for depression. AIM: To evaluate the safety of flibanserin in women treated for depression with selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors. METHODS: In this double-blinded, randomized, placebo-controlled trial, women with remitted or mild depression treated with selective serotonin reuptake inhibitors or serotonin and norepinephrine reuptake inhibitors who were not postmenopausal and were experiencing symptoms of hypoactive sexual desire disorder (ie, decreased sexual desire and related distress) received flibanserin 50 mg at bedtime (qhs) for 2 weeks and up-titrated to 100 mg qhs, flibanserin 100 mg qhs for the entire treatment period, or placebo for up to 12 weeks...
January 2018: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29288108/sexual-dysfunction-after-good-grade-aneurysmal-subarachnoid-hemorrhage
#3
Lorenz Epprecht, Michael Messerli, Robin Samuel, Martin Seule, Johannes Weber, Jean-Yves Fournier, Werner Surbeck
OBJECTIVE: Our aim was to assess the consequences of aneurysmal subarachnoid hemorrhage (aSAH) on sexual pleasure in patients with an otherwise favorable neurological outcome. METHODS: Anonymous, standardized questionnaires concerning sexual function, including the International Index of Erectile Function, Female Sexual Function Index, and a statement on subjective change in sexual pleasure after aSAH, were completed by 33 patients treated at the Cantonal Hospital St...
December 26, 2017: World Neurosurgery
https://www.readbyqxmd.com/read/29278235/role-of-hormones-in-hypoactive-sexual-desire-disorder-and-current-treatment
#4
Ahmed AlAwlaqi, Houda Amor, Mohamed E Hammadeh
Over the decades, female sexual dysfunction (FSD) has grown to be an increasingly potential problem that complicates the quality of life among women. In the current review, FSD refers to recurrent and persistent problems with sexual orgasm, desire, or response. One of the most common subtypes of FSD that has evoked increased research interest in the scientific community is hyposexuality. Today, there is a consensus that hyposexuality is a multifactorial condition that manifests with reduced sexual desire resulting in significant interpersonal distress...
December 15, 2017: Journal of the Turkish German Gynecological Association
https://www.readbyqxmd.com/read/29198512/understanding-the-role-of-serotonin-in-female-hypoactive-sexual-desire-disorder-and-treatment-options
#5
REVIEW
Harry A Croft
BACKGROUND: The neurobiology of sexual response is driven in part by dopamine and serotonin-the former modulating excitatory pathways and the latter regulating inhibitory pathways. Neurobiological underpinnings of hypoactive sexual desire disorder (HSDD) are seemingly related to overactive serotonin activity that results in underactive dopamine activity. As such, pharmacologic agents that decrease serotonin, increase dopamine, or some combination thereof, have therapeutic potential for HSDD...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29198504/female-sexual-dysfunction-medical-and-psychological-treatments-committee-14
#6
Sheryl A Kingsberg, Stanley Althof, James A Simon, Andrea Bradford, Johannes Bitzer, Joana Carvalho, Kathryn E Flynn, Rossella E Nappi, Jennifer B Reese, Roya L Rezaee, Leslie Schover, Jan L Shifrin
INTRODUCTION: Since the millennium we have witnessed significant strides in the science and treatment of female sexual dysfunction (FSD). This forward progress has included (i) the development of new theoretical models to describe healthy and dysfunctional sexual responses in women; (ii) alternative classification strategies of female sexual disorders; (iii) major advances in brain, hormonal, psychological, and interpersonal research focusing on etiologic factors and treatment approaches; (iv) strong and effective public advocacy for FSD; and (v) greater educational awareness of the impact of FSD on the woman and her partner...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/29198449/effects-of-flibanserin-on-the-pharmacokinetics-of-a-combined-ethinylestradiol-levonorgestrel-oral-contraceptive-in-healthy-premenopausal-women-a-randomized-crossover-study
#7
Crista Johnson-Agbakwu, Louise Brown, James Yuan, Robert Kissling, David J Greenblatt
PURPOSE: This study aimed to investigate the effect of steady-state exposure to flibanserin, a 5-HT1A agonist/5-HT2A antagonist approved for the treatment of hypoactive sexual desire disorder in premenopausal women, on the single-dose pharmacokinetics of the contraceptive steroids ethinylestradiol and levonorgestrel in healthy premenopausal women. METHODS: Healthy female volunteers (N = 24) received 2 single doses of a combined oral contraceptive containing ethinylestradiol 30 μg and levonorgestrel 150 μg, either alone (reference) or preceded by treatment with flibanserin 100 mg once daily for 14 days (test)...
November 30, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/29172782/efficacy-of-tribulus-terrestris-for-the-treatment-of-premenopausal-women-with-hypoactive-sexual-desire-disorder-a-randomized-double-blinded-placebo-controlled-trial
#8
Fabiene Bernardes Castro Vale, Karla Zanolla Dias de Souza, Camilla Russi Rezende, Selmo Geber
Although hypoactive sexual desire disorder (HSDD) is the most common sexual complaint, there is no consensus for the ideal treatment. Our study aimed to evaluate the efficacy of treating premenopausal women with HSDD with Tribulus terrestris and its effect on the serum levels of testosterone. We performed a prospective, randomized, double-blind, placebo-controlled trial, with 40 premenopausal women reporting diminished libido, receiving T. terrestris or placebo. The questionnaires FSFI and the QS-F were used to evaluate sexual dysfunction before and after treatment...
November 27, 2017: Gynecological Endocrinology
https://www.readbyqxmd.com/read/29095039/women-with-hypoactive-sexual-desire-disorder-versus-sexual-interest-arousal-disorder-an-empirical-test-of-raising-the-bar
#9
Julia I O'Loughlin, Rosemary Basson, Lori A Brotto
In 2013, the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) was published with a major revision to the sexual dysfunction categories, and the diagnosis of female hypoactive sexual desire disorder (HSDD) was replaced with female sexual interest/arousal disorder (SIAD). Since being introduced, concern has been expressed that SIAD inappropriately "raises the bar" for diagnosis. To address these concerns, we sought to evaluate the number of women with a diagnosis of HSDD who also met criteria for SIAD...
November 2, 2017: Journal of Sex Research
https://www.readbyqxmd.com/read/29094914/testosterone-therapy-review-of-clinical-applications
#10
REVIEW
Ryan C Petering, Nathan A Brooks
Testosterone therapy is increasingly common in the United States, and many of these prescriptions are written by primary care physicians. There is conflicting evidence on the benefit of male testosterone therapy for age-related declines in testosterone. Physicians should not measure testosterone levels unless a patient has signs and symptoms of hypogonadism, such as loss of body hair, sexual dysfunction, hot flashes, or gynecomastia. Depressed mood, fatigue, decreased strength, and a decreased sense of vitality are less specific to male hypogonadism...
October 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/29080672/fezf1-is-a-novel-regulator-of-female-sex-behavior-in-mice
#11
Tomaz Büdefeld, Tanja Spanic, Milka Vrecl, Gregor Majdic
Female sexual behavior is a complex process regulated by multiple brain circuits and influenced by sex steroid hormones acting in the brain. Several regions in the hypothalamus have been implicated in the regulation of female sexual behavior although a complete circuitry involved in female sexual behavior is not understood. Fez family zinc finger 1 (Fezf1) gene is a brain specific gene that has been mostly studied in the context of olfactory development, although in a recent study, FEZF1 has been identified as one of the genes responsible for the development of Kallman syndrome...
November 13, 2017: Hormones and Behavior
https://www.readbyqxmd.com/read/29066935/female-sexual-dysfunction-a-focus-on-flibanserin
#12
REVIEW
Nicole M Lodise
Flibanserin is the first US Food and Drug Administration (FDA)-approved option for sexual dysfunction, specifically low sexual desire. Until recently, there were no FDA-approved medication options to assist the ~40% of women affected by female sexual dysfunction (FSD). Often, patients report feeling uncomfortable discussing sexual health, identifying a strong need for health care professionals (HCPs) to proactively reach out to patients to identify concerns and initiate a discussion about sexual health and the available treatment options...
2017: International Journal of Women's Health
https://www.readbyqxmd.com/read/29066307/aromatase-inhibitors-are-associated-with-low-sexual-desire-causing-distress-and-fecal-incontinence-in-women-an-observational-study
#13
Penelope J Robinson, Robin J Bell, Marie K Christakis, Stephanie R Ivezic, Susan R Davis
BACKGROUND: Little is known of the impact of aromatase inhibitor (AI) therapy on sexual and pelvic floor function. AIM: To document the prevalence of, and factors associated with, low desire, sexually related personal distress, hypoactive sexual desire dysfunction (HSDD), and pelvic floor dysfunction in women 10 years after breast cancer diagnosis. METHODS: This was a prospective, observational, community-based cohort study of Australian women with invasive breast cancer recruited within 12 months of diagnosis...
December 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28993148/the-sexual-event-diary-sed-development-and-validation-of-a-standardized-questionnaire-for-assessing-female-sexual-functioning-during-discrete-sexual-events
#14
Yvonne van Nes, Jos Bloemers, Peter G M van der Heijden, Kim van Rooij, Jeroen Gerritsen, Rob Kessels, Leonard DeRogatis, Adriaan Tuiten
BACKGROUND: The efficacy of on-demand drugs for hypoactive sexual desire disorder (HSDD) or female sexual interest/arousal disorder (FSIAD) should be assessed using a validated instrument that assesses the discrete sexual events during which the on-demand drug is taken. AIM: To develop and validate an event log for measuring sexual satisfaction and sexual functioning of discrete sexual events. METHODS: Psychometric assessment was carried out on data of 10,959 Sexual Event Diaries (SEDs) collected during three clinical trials in a total of 421 women with HSDD...
November 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28923310/factors-associated-with-specific-diagnostic-and-statistical-manual-of-mental-disorders-fourth-edition-sexual-dysfunctions-in-breast-cancer-survivors-a-study-of-patients-and-their-partners
#15
Susanna B Hummel, Daniela E E Hahn, Jacques J D M van Lankveld, Hester S A Oldenburg, Eva Broomans, Neil K Aaronson
BACKGROUND: Many women develop sexual problems after breast cancer (BC) treatment. Little is known about BC survivors with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) sexual dysfunction and their partners, and the factors associated with their sexual functioning. AIM: To evaluate (i) patient-related and clinical factors associated with (a) specific DSM-IV sexual dysfunctions and (b) level of sexual functioning and sexual distress as reported by BC survivors and (ii) the association between the sexual functioning of BC survivors and that of their partners...
October 2017: Journal of Sexual Medicine
https://www.readbyqxmd.com/read/28918588/a-practical-approach-to-managing-hypoactive-sexual-desire-disorder-in-women-with-diabetes
#16
REVIEW
Charmaine Rochester-Eyeguokan, Lisa Meade
Female sexual dysfunction (FSD) is highly prevalent in women with diabetes mellitus (DM), yet it remains unaddressed, undiagnosed, and untreated. Hypoactive sexual desire disorder (HSDD) is the most common complaint among women with FSD, but there is a paucity of research into its multifactorial etiology. Flibanserin is the only therapy approved by the US Food and Drug Administration for treating acquired, generalized HSDD in premenopausal women. Women with DM diagnosed with HSDD may require a multidisciplinary approach for optimal management...
October 2017: Diabetes Therapy: Research, Treatment and Education of Diabetes and related Disorders
https://www.readbyqxmd.com/read/28885410/distressing-sexual-function-at-midlife-unmet-needs-practical-diagnoses-and-available-treatments
#17
James A Simon, Vanessa A Lukas
Female sexual dysfunction (FSD) is characterized as chronic sexual symptoms that manifest with personal distress in the domains of desire, arousal, orgasm, and pain. Extensive epidemiologic evidence estimates that almost 50% of perimenopausal and postmenopausal women experience FSD. Screening for FSD is not readily conducted and patient-physician discussion of sexuality is limited by the lack of physician training on the topic and by the patient-held belief that sexual issues are not medical in nature. The purpose of this commentary is to provide clinicians with a framework to approach the discussion of FSD, to clinically identify FSD through patient symptoms and physical signs, and to manage FSD in perimenopausal and postmenopausal patients with the available U...
October 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28865901/neuroimaging-of-female-sexual-desire-and-hypoactive-sexual-desire-disorder
#18
REVIEW
Stephanie Cacioppo
INTRODUCTION: Recent advances in neuroimaging offer an unprecedented window into the female sexual brain. The small samples and poor statistical power of individual functional magnetic resonance imaging studies have limited what can be gleaned about the systematic brain network that is involved in female sexual desire and female sexual dysfunction (eg, hypoactive sexual desire disorder [HSDD]). AIM: To quantitatively determine the brain network involved in HSDD...
August 30, 2017: Sexual Medicine Reviews
https://www.readbyqxmd.com/read/28817365/effect-of-flibanserin-treatment-on-body-weight-in-premenopausal-and-postmenopausal-women-with-hypoactive-sexual-desire-disorder-a-post-hoc-analysis
#19
Susan G Kornstein, James A Simon, Stuart C Apfel, James Yuan, Krista A Barbour, Robert Kissling
BACKGROUND: Flibanserin, a 5-HT1A agonist and 5-HT2A antagonist, is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. This post hoc analysis evaluated the effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with HSDD. MATERIALS AND METHODS: This analysis included three 24-week, double-blind, placebo-controlled studies of flibanserin 100 mg each bedtime (qhs) in premenopausal women, a similarly designed study in postmenopausal women, and a 52-week, open-label extension study in premenopausal women...
November 2017: Journal of Women's Health
https://www.readbyqxmd.com/read/28814122/flibanserin-toxicity-in-a-toddler-following-ingestion
#20
Nicholas Granzella, Betty C Chen, Geoffrey S Baird, Matthew Valento
INTRODUCTION: Flibanserin is a medication recently approved by the FDA for treatment of generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. Its mechanism of action is not fully understood but is thought to modulate serotonin receptors and increase levels of norepinephrine and dopamine. While much is known about toxicity of other drugs which affect these systems, there is little information about toxicity of flibanserin at this time. CASE: We present a case of a 2-year-old boy who ingested an estimated 600 mg of his mother's flibanserin...
August 17, 2017: Clinical Toxicology
keyword
keyword
113009
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"